R1 RCM, Health Catalyst Downgraded as KeyBanc Reviews Health-tech Space
Seeking AlphaApr 10 12:56 ET
What 7 Analyst Ratings Have To Say About Health Catalyst
BenzingaApr 10 11:00 ET
Cantor Fitzgerald Reiterates Overweight on Health Catalyst, Maintains $16 Price Target
BenzingaApr 10 10:16 ET
Health Catalyst Analyst Ratings
BenzingaApr 10 04:41 ET
Health Catalyst Analyst Ratings
BenzingaMar 5 12:35 ET
Buy Rating on Health Catalyst: Strategic Innovation and Client Growth Poised to Drive Performance
TipRanksMar 5 06:06 ET
Barclays Issues a Buy Rating on Health Catalyst (HCAT)
TipRanksMar 5 03:15 ET
RBC Capital Remains a Hold on Health Catalyst (HCAT)
TipRanksFeb 26 07:36 ET
Maintaining Buy Rating on Health Catalyst: Strong Sales Pipeline and Margin Outlook Offset Slower Growth Forecast
TipRanksFeb 26 06:35 ET
Keybanc Maintains Overweight on Health Catalyst, Lowers Price Target to $10
BenzingaFeb 26 05:19 ET
Health Catalyst Analyst Ratings
BenzingaFeb 23 09:42 ET
Optimistic Outlook: Health Catalyst's Growth and Profitability Potential Affirm Buy Rating
TipRanksFeb 23 07:49 ET
Stifel Nicolaus Remains a Hold on Health Catalyst (HCAT)
TipRanksFeb 23 07:33 ET
Piper Sandler Sticks to Their Buy Rating for Health Catalyst (HCAT)
TipRanksFeb 23 07:33 ET
Health Catalyst (HCAT) Receives a Buy From Barclays
TipRanksFeb 23 03:05 ET
Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT), Regeneron (REGN) and Merck & Company (MRK)
TipRanksFeb 15 03:20 ET
Stifel Nicolaus Sticks to Its Hold Rating for Health Catalyst (HCAT)
TipRanksFeb 7 08:41 ET
Health Catalyst Analyst Ratings
BenzingaJan 26 05:30 ET
Analysts Conflicted on These Healthcare Names: Karuna Therapeutics (KRTX) and Health Catalyst (HCAT)
TipRanksJan 26 04:50 ET
Health Catalyst (HCAT) Gets a Buy From Piper Sandler
TipRanksJan 10 07:18 ET
No Data
No Data